At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 258 enrolled
Drug / intervention
AZD8108 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD8108 in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating AZD8108 and Placebo for Healthy Volunteers. Completed, enrolled 258 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD8108 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD8108 or placebo will be administered orally as a solution, and a 4- to 10-day follow-up period after discharge.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartNov 2014
Primary CompletionSep 2015
TodayJul 2026
First PostedSep 25, 2014
Enrollment StartNov 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.8 years ago
Interventions
AZD8108drug
Drug: AZD8108 Single or Multiple doses administered orally as a solution.
Placebodrug
Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution